Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0130

Advisory board · Dr. Daniel Kimura

23 Jan 2026 · In person · Dr. Daniel Kimura, UCLH · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0130—

Capture insight from this engagement

Location: UCLH
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
APRIL pathway mechanism

Scientific content used

NPH mechanism-of-action deck
APRIL-IgAN Phase III topline

Questions raised

What is the immunoglobulin monitoring recommendation?
Is there any data on APRIL inhibition in FSGS?

Notes

Advisory board with academic nephrologist at UCLH. Discussed patient-reported outcomes, april pathway mechanism.

Insights captured (1)

Capture insight

INS-0011Critical
Patient-reported outcomes
Patient-reported outcomes: practice variation observed reported by academic nephrologist (GB).
Action in progress

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 5
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0130

Audit history (0)

All create, update and approval events for this record

No audit events in sample data